NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
22 trialsNCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04383119 2026-01-02
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06524583 2025-03-30
L-UteCIN
UNICANCER
Phase 2 Recruiting
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT05131386 2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
NCT02359474 2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT02247544 2021-11-01
TRAVELL
Italian Sarcoma Group
Phase 2 Completed
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00070109 2018-09-14
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01104298 2015-10-27
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Terminated
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00786838 2014-04-11
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00017030 2013-06-26
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005625 2013-06-19
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed